Abiraterone acts as a selective inhibitor of the enzyme CYP17A1 for prostate cancer. Targeted enzymatic blockade prevents hormone synthesis, restricting the fuel source for specific malignant cellular growth.
Abiraterone belongs to a class of compounds known as adrenal steroidogenesis inhibitors. It serves as an active substance used to address certain forms of prostate cancer. By interfering with specific biological pathways, this compound aims to reduce the production of androgens in the body.
The substance functions primarily by targeting an enzyme involved in the creation of hormones like testosterone. Because some tumor cells in the prostate rely on these hormones to thrive, restricting their availability can assist in managing the condition. It is commonly found in formulations such as Abiraterone acetate tablets.
In Singapore, this active substance is typically accessed through specialized healthcare channels as a targeted therapy. It is most frequently encountered in the form of oral tablets. These medications are manufactured to ensure consistent release of the active compound within the digestive system.
Patients may encounter different brand names for products containing this ingredient. While the brand names might differ, the core active principle remains the same. The strength of these tablets is standardized to support individual treatment plans designed by oncology teams.
This compound is utilized for patients diagnosed with advanced stages of prostate cancer. It is often employed in situations where the cancer has spread or is no longer responding to initial hormone-based therapies.
The substance is frequently used in the following contexts:
It is intended for use in adult populations. The goal is to inhibit the progression of the disease and address symptoms associated with increased tumor growth.
The biological effect of this substance is centered on the inhibition of a protein called CYP17A1. This enzyme is essential for the biosynthesis of androgens throughout the body, including the testes, adrenal glands, and the tumor cells themselves.
By blocking this enzyme, the compound effectively lowers the levels of circulating testosterone and other related hormones. Reducing these levels helps limit the stimulation that drives the progression of specific prostate malignancies. This systemic approach is designed to cut off the hormonal "fuel" that these cells need to multiply.
Some individuals may experience effects such as joint swelling or discomfort, fluid retention, or changes in blood chemistry. High blood pressure or feelings of fatigue are also reported. These reactions are often tracked during regular monitoring visits.
While less frequent, there are significant signs that require prompt medical awareness. These include symptoms of liver inflammation-such as yellowing of the skin or eyes-and signs of heart strain. Persistent swelling in the legs or feet should also be reported to a professional.
This substance is not suitable for individuals with severe pre-existing liver impairment. It is also generally avoided in women who are pregnant or may become pregnant, as it can affect fetal development.
This compound can interact with various other substances, including those metabolized by the same liver enzymes. Alcohol and certain herbal supplements may also alter how the body processes the medication. Always check the specific patient information leaflet included with the medication for a full list of known interactions.
The duration of therapy depends on how the condition responds to the medication and the patient's individual health status. It is typically a long-term approach for managing advanced-stage cancer. Proper storage involves keeping the tablets in a cool, dry place away from direct light and out of the reach of children.
For detailed usage, dosage, and administration, always refer to the specific medication’s clinical information or packaging. Follow the instructions provided by the oncology team regarding when and how to take each dose.
This document provides a general educational overview concerning Abiraterone and does not constitute medical advice. Individual medications containing this substance may vary in formulation, strength, and specific administration requirements. We do not assume liability for clinical decisions or individual outcomes. Patients should strictly follow the labeling provided with their specific medication and obtain guidance from a healthcare professional regarding their unique clinical situation and treatment needs.
